Pieris Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Pieris Pharmaceuticals's estimated annual revenue is currently $17.4M per year.
- Pieris Pharmaceuticals received $50.6M in venture funding in February 2018. 0
- Pieris Pharmaceuticals's total funding is $194.3M.
Employee Data
- 00
Pieris Pharmaceuticals's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP | Reveal Email/Phone |
2 | Head Selection Technologies / Project Leader | Reveal Email/Phone |
3 | VP Respiratory Medicine | Reveal Email/Phone |
4 | VP, Head Alliance Management and Early-Stage Project Leadership | Reveal Email/Phone |
5 | Head Quality Assurance | Reveal Email/Phone |
6 | VP Talent & Organizational Development | Reveal Email/Phone |
7 | Chief Financial Officer | Reveal Email/Phone |
8 | SVP, Chief Business Officer and General Counsel | Reveal Email/Phone |
9 | Senior Director, Commercial & Strategy | Reveal Email/Phone |
10 | Associate Director, FP&A | Reveal Email/Phone |
Pieris Pharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Pieris Pharmaceuticals?
Pieris Pharmaceuticals (NASDAQ: PIRS) is a clinical stage biotechnology company that discovers and develops Anticalin-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Proprietary to Pieris, Anticalin proteins are a novel class of therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. Pieris is listed on the NASDAQ and trades under the ticker symbol PIRS. Pieris is currently hiring in Boston and Freising, Germany. See here for our full list of job openings and information on applying: https://www.pieris.com/careers
keywords:Biotechnology,Healthcare,Pharmaceuticals
$194.3M
Total Funding
N/A
Number of Employees
$17.4M
Revenue (est)
N/A
Employee Growth %
N/A
Valuation
N/A
Accelerator
Pieris Pharmaceuticals News
Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops...
Pieris Pharmaceuticals ( PIRS -4.03% ) is a micro-cap stock, but with big pharma now collaborating with the company, it may be time to...
Because Pieris Pharmaceuticals made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue...
November 11, 2021 Pieris Pharmaceuticals To Participate In Upcoming Investor Conferences BOSTON, MA / ACCESSWIRE /November 11, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technolog ...
November 8, 2021 Pieris Pharmaceuticals and Servier Announce Dosing of First Patient in Phase 1/2 Trial of 4-1BB/PD-L1 Bispecific PRS- 344/S095012 BOSTON, MA and PARIS, FRANCE / ACCESSWIRE / November 8, 2021 /Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company a ...
Other Companies in Boston
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $77M | 0 | N/A | $866M |
#2 | $7.4M | 0 | N/A | $0.5M |
#3 | $5.5M | 0 | N/A | $86.3M |
#4 | $66.9M | 0 | N/A | $142M |
#5 | $26.4M | 0 | N/A | $38M |
Pieris Pharmaceuticals Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2016-06-20 | $16.5M | Undisclosed | Article | |
| 2018-02-22 | $50.6M | Undisclosed | Article |